



CLAIMS

1. A pharmaceutical product comprising an anti-TROP2 antibody-drug conjugate and a PARP1 selective inhibitor for administration in combination, wherein the anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A represents the connecting position to an antibody, is conjugated to an anti-TROP2 antibody via a thioether bond, wherein the PARP1 selective inhibitor is a compound represented by the following formula (I):



(I)

wherein:


X^1 and X^2 are each independently selected from N and $C(H)$,

X^3 is independently selected from N and $C(R^4)$, wherein R^4 is H or fluoro,
 R^1 is C_{1-4} alkyl or C_{1-4} fluoroalkyl,
 R^2 is independently selected from H, halo, C_{1-4} alkyl, and C_{1-4} fluoroalkyl, and
 R^3 is H or C_{1-4} alkyl,
or a pharmaceutically acceptable salt thereof
provided that:

when X^1 is N, then X^2 is $C(H)$, and X^3 is $C(R^4)$,
when X^2 is N, then X^1 is $C(H)$, and X^3 is $C(R^4)$, and
when X^3 is N, then X^1 and X^2 are both $C(H)$, and

wherein the anti-TROP2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of an amino acid sequence represented by SEQ ID NO: 3, CDRH2 consisting of an amino acid sequence represented by SEQ ID NO: 4 and CDRH3 consisting of an amino acid sequence represented by SEQ ID NO: 5, and a light chain comprising CDRL1 consisting of an amino acid sequence represented by SEQ ID NO: 6, CDRL2 consisting of an amino acid sequence represented by SEQ ID NO: 7 and CDRL3 consisting of an amino acid sequence represented by SEQ ID NO: 8.

2. The pharmaceutical product according to claim 1, wherein the PARP1 selective inhibitor is AZD5305, also known as AZ14170049, represented by the following formula:



or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical product according to claim 1 or 2, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence represented by SEQ ID NO: 9 and a light chain comprising a light chain variable region consisting of an amino acid sequence represented by SEQ ID NO: 10.

4. The pharmaceutical product according to claim 3, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 12 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 13 or an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 11 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 13.

5. The pharmaceutical product according to any one of claims 1 to 4, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 2 to 8.

6. The pharmaceutical product according to claim 5, wherein the average number of units of the drug-linker

conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.

7. The pharmaceutical product according to claim 6, wherein the anti-TROP2 antibody-drug conjugate is datopotamab deruxtecan (DS-1062).

8. The pharmaceutical product according to any one of claims 1 to 7 wherein the product is a combined preparation comprising the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor, for sequential or simultaneous administration.

9. The pharmaceutical product according to any one of claims 1 to 8 wherein the anti-TROP2 antibody-drug conjugate is to be administered at a dose of 6 mg/kg body weight.

10. The pharmaceutical product according to claim 9 wherein the dose of the anti-TROP2 antibody-drug conjugate is to be administered once every three weeks.

11. The pharmaceutical product according to any one of claims 1 to 10 wherein the PARP1 selective inhibitor is to be administered daily for the first week, second week, and/or third week of a three week cycle.

12. A pharmaceutical product according to any one of claims 1 to 11 for use in the treatment of cancer.

13. Use of an anti-TROP2 antibody-drug conjugate, in combination with a PARP1 selective inhibitor, in the manufacture of a combination pharmaceutical composition for the treatment of cancer, wherein the anti-TROP2

antibody-drug conjugate and the PARP1 selective inhibitor are as defined in any one of claims 1 to 7.

14. Use of a PARP1 selective inhibitor, in combination with an anti-TROP2 antibody-drug conjugate, in the manufacture of a combination pharmaceutical composition for the treatment of cancer, wherein the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor are as defined in any one of claims 1 to 7.

15. The use according to claim 13 or 14, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, colorectal cancer, gastric cancer, esophageal cancer, head-and-neck cancer, esophagogastric junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, digestive tract stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, corpus uteri carcinoma, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, endometrial cancer and melanoma.

16. The use according to claim 15, wherein the breast cancer is triple negative breast cancer or hormone receptor (HR)-positive, HER2-negative breast cancer.

17. The use according to claim 15, wherein the lung cancer is non-small cell lung cancer.

18. The use according to claim 17, wherein the non-small cell lung cancer is non-small cell lung cancer with actionable genomic alterations or non-small cell lung cancer without actionable genomic alterations.

19. The use according to claim 15, wherein the cancer is gastric cancer.

20. The use according to claim 15, wherein the cancer is ovarian cancer.

21. The use according to any one of claims 15 to 20, wherein the cancer is deficient in Homologous Recombination (HR) dependent DNA DSB repair activity.

22. The use according to any one of claims 15 to 20, wherein the cancer is not deficient in Homologous Recombination (HR) dependent DNA DSB repair activity.

23. The use according to any one of claims 15 to 20, wherein the cancer exhibits resistance or refractoriness to a previous treatment with a PARP inhibitor.

24. The use according to claim 23, wherein the previous treatment is with a PARP inhibitor selected from olaparib, rucaparib, niraparib, talazoparib and veliparib.

25. The use according to any one of claims 13 to 24, wherein the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor are to be administered sequentially or simultaneously, optionally wherein when the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor are to be administered sequentially, the PARP1 selective inhibitor is to be administered first

and the anti-TROP2 antibody-drug conjugate is to be administered second, or the anti-TROP2 antibody-drug conjugate is to be administered first and the PARP1 selective inhibitor is to be administered second.

26. The use according to any one of claims 13 to 25 wherein the anti-TROP2 antibody-drug conjugate is to be administered at a dose of 6 mg/kg body weight.

27. The use according to claim 26 wherein the dose of the anti-TROP2 antibody-drug conjugate is to be administered once every three weeks.

28. The use according to any one of claims 13 to 27 wherein the PARP1 selective inhibitor is to be administered daily for the first week, second week, and/or third week of a three week cycle.